Decreased serum fetuin-A levels after a single haemodialysis session

rapid half-life of DXL (about 4min) causing no accumulation of the drug in the central compartment after repeated administration. So these differences in DXL plasma concentrations looked accidental. The observed transient increase of DXL plasma concentrations during HD is probably due to altered protein binding of the drug. To evaluate DXL toxicity, blood-count controls were taken in periodic intervals. Grade 2 leucoand thrombocytopaenia (National Cancer Institute Common Toxicity Criteria, NCI–CTC) were detected 10–20 days after the second cycle of chemotherapy (data not shown). Restaging at day 42 revealed further regression of the central tumour and a decreased bronchial wall thickness. The mediastinal lymph nodes remained stable and a restaging mediastinoscopy showed necrosis but also residual tumour cells. Afterwards, sequential radiotherapy of the mediastinum and the primary completed the treatment. In conclusion, a carboplatin/DXL combination might be a suitable regimen for NSCLC patients undergoing HD.